A Two-part, Phase 1, Open-label, Randomized, Parallel-arm, Fixed Sequence, Drug-drug Interaction Study to Investigate the Effect of Linerixibat on Plasma Concentrations of Obeticholic Acid and Conjugates in Healthy Adult Participants
Latest Information Update: 09 Nov 2022
At a glance
- Drugs Linerixibat (Primary) ; Obeticholic acid (Primary)
- Indications Alcoholic hepatitis; Biliary atresia; Cholelithiasis; Crohn's disease; Non-alcoholic steatohepatitis; Obesity; Portal hypertension; Primary bile acid malabsorption; Primary biliary cirrhosis; Primary sclerosing cholangitis; Pruritus; Reperfusion injury; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 04 Nov 2022 Status changed from recruiting to completed.
- 10 Jun 2022 Planned End Date changed from 4 Oct 2022 to 30 Nov 2022.
- 10 Jun 2022 Planned primary completion date changed from 4 Oct 2022 to 30 Nov 2022.